Shakuyaku-Kanzo-TO


Indications and Reactions:

Role Indications Reactions
Secondary
Hypertension 17.7%
Osteoporosis 10.6%
Depression 7.1%
Aplastic Anaemia 6.2%
Hyperlipidaemia 6.2%
Antibiotic Prophylaxis 5.3%
Muscle Spasms 5.3%
Back Pain 4.4%
Insomnia 4.0%
Constipation 3.5%
Gastritis 3.5%
Rectal Cancer Metastatic 3.5%
Spinal Osteoarthritis 3.5%
Nasopharyngitis 3.1%
Asthma 2.7%
Diabetic Neuropathy 2.7%
Dizziness 2.7%
Drug Use For Unknown Indication 2.7%
Irritable Bowel Syndrome 2.7%
Myalgia 2.7%
Pseudoaldosteronism 22.4%
Hypokalaemia 8.2%
Oedema 8.2%
Torsade De Pointes 8.2%
Hallucination 6.1%
Ventricular Tachycardia 6.1%
Electrocardiogram Qt Prolonged 4.1%
Metabolic Alkalosis 4.1%
Quadriplegia 4.1%
Rhabdomyolysis 4.1%
Tremor 4.1%
White Blood Cell Count Decreased 4.1%
Drug Interaction 2.0%
Eosinophilic Pneumonia 2.0%
Long Qt Syndrome 2.0%
Myoglobin Blood Increased 2.0%
Myoglobin Urine Present 2.0%
Myopathy 2.0%
Nausea 2.0%
Paralysis 2.0%
Concomitant
Prophylaxis 14.5%
Hypertension 8.8%
Muscle Spasms 6.8%
Osteoporosis 6.4%
Diabetes Mellitus 5.1%
Insomnia 5.1%
Chronic Hepatitis C 4.9%
Gastric Ulcer 4.9%
Renal Impairment 4.7%
Rheumatoid Arthritis 4.5%
Constipation 4.3%
Multiple Myeloma 4.3%
Hepatitis C 4.1%
Analgesic Therapy 3.5%
Hepatic Neoplasm Malignant 3.5%
Pain 3.3%
Drug Use For Unknown Indication 3.1%
Hypoaesthesia 3.1%
Ascites 2.7%
Chronic Obstructive Pulmonary Disease 2.3%
Osteonecrosis 8.8%
Pyrexia 8.8%
Lipase Increased 7.5%
White Blood Cell Count Decreased 7.5%
Rhabdomyolysis 6.3%
Gastrointestinal Necrosis 5.0%
Osteomyelitis 5.0%
Palmar-plantar Erythrodysaesthesia Syndrome 5.0%
Pneumothorax 5.0%
Atypical Femur Fracture 3.8%
Cardiac Failure 3.8%
Gastric Ulcer Haemorrhage 3.8%
Liver Disorder 3.8%
Loss Of Consciousness 3.8%
Neutropenia 3.8%
Pneumonia 3.8%
Pulmonary Embolism 3.8%
Speech Disorder 3.8%
Tumour Haemorrhage 3.8%
Upper Respiratory Tract Inflammation 3.8%

Drug Data